Parkash Om, Sharko Artem, Farooqi Aneeba, Ying Grace W, Sura Prashant
Internal Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA.
Internal Medicine, Rosalind Franklin University of Medicine and Science, Northwestern Medicine McHenry Hospital, McHenry, USA.
Cureus. 2021 Apr 28;13(4):e14741. doi: 10.7759/cureus.14741.
For the first time, the mRNA technology was utilized to produce a vaccine against COVID-19 after the unprecedented pandemic equally affected every part of the world. Pfizer-BioNTech (BNT162b2) mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was granted emergency use authorization (EUA) by Food and Drug Administration (FDA) in December 2020. EUA has been widely discussed in the medical literature and the general public. The safety of the BNT162b2 vaccine has been investigated in short-term trials with data available for three months. We present a case of a 96-year-old female with a past surgical history of cholecystectomy who presented with acute onset severe abdominal pain a few days after getting the first dose of Pfizer-BioNTech COVID-19 vaccine. She was diagnosed with acute pancreatitis with a lipase level of 4036 U/L. Extensive history and investigations were unable to find any etiology. The patient was conservatively managed and discharged home without any complications. There has been some data available in medical literature showing an association between acute pancreatitis and COVID-19 infection. Trial data of Pfizer COVID-19 also shows one case of acute pancreatitis in the treatment group. There have also been individual cases of unexplained acute pancreatitis shared by medical professionals on online forums. Our main goal to write this case is to make medical literature aware of possible emerging side effects of the COVID-19 vaccine, one of such side effects being self-resolving uncomplicated acute pancreatitis.
在这场前所未有的大流行对世界各个角落都产生了影响之后，首次利用信使核糖核酸（mRNA）技术生产出了针对2019冠状病毒病（COVID-19）的疫苗。辉瑞-生物科技公司（BNT162b2）针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的mRNA疫苗于2020年12月获得美国食品药品监督管理局（FDA）的紧急使用授权（EUA）。EUA在医学文献和普通公众中都得到了广泛讨论。BNT162b2疫苗的安全性已在短期试验中进行了调查，有三个月的数据可用。我们报告一例96岁女性病例，该患者有胆囊切除术的既往手术史，在接种第一剂辉瑞-生物科技公司COVID-19疫苗几天后出现急性发作的严重腹痛。她被诊断为急性胰腺炎，脂肪酶水平为4036 U/L。广泛的病史询问和检查未能发现任何病因。患者接受了保守治疗，出院时无任何并发症。医学文献中有一些数据显示急性胰腺炎与COVID-19感染之间存在关联。辉瑞COVID-19疫苗的试验数据也显示治疗组有一例急性胰腺炎病例。医学专业人员在在线论坛上也分享了一些不明原因急性胰腺炎的个别病例。我们撰写本病例的主要目的是让医学文献了解COVID-19疫苗可能出现的新副作用，其中一种副作用是可自行缓解的无并发症急性胰腺炎。
